Investors Holding Back On Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 40x, you may consider Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) as a highly attractive investment with its 15.5x P/E ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/E.

Recent times haven't been advantageous for Jianmin Pharmaceutical GroupLtd as its earnings have been falling quicker than most other companies. The P/E is probably low because investors think this poor earnings performance isn't going to improve at all. You'd much rather the company wasn't bleeding earnings if you still believe in the business. If not, then existing shareholders will probably struggle to get excited about the future direction of the share price.

View our latest analysis for Jianmin Pharmaceutical GroupLtd

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Jianmin Pharmaceutical GroupLtd.

What Are Growth Metrics Telling Us About The Low P/E?

In order to justify its P/E ratio, Jianmin Pharmaceutical GroupLtd would need to produce anemic growth that's substantially trailing the market.

Retrospectively, the last year delivered a frustrating 16% decrease to the company's bottom line. However, a few very strong years before that means that it was still able to grow EPS by an impressive 53% in total over the last three years. So we can start by confirming that the company has generally done a very good job of growing earnings over that time, even though it had some hiccups along the way.

Looking ahead now, EPS is anticipated to climb by 43% during the coming year according to the one analyst following the company. That's shaping up to be materially higher than the 37% growth forecast for the broader market.

With this information, we find it odd that Jianmin Pharmaceutical GroupLtd is trading at a P/E lower than the market. Apparently some shareholders are doubtful of the forecasts and have been accepting significantly lower selling prices.

The Bottom Line On Jianmin Pharmaceutical GroupLtd's P/E

Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

We've established that Jianmin Pharmaceutical GroupLtd currently trades on a much lower than expected P/E since its forecast growth is higher than the wider market. There could be some major unobserved threats to earnings preventing the P/E ratio from matching the positive outlook. At least price risks look to be very low, but investors seem to think future earnings could see a lot of volatility.

Before you take the next step, you should know about the 2 warning signs for Jianmin Pharmaceutical GroupLtd (1 is a bit concerning!) that we have uncovered.

If P/E ratios interest you, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.